Flovent HFA

DRUG2 trials

Sponsors

Teva Branded Pharmaceutical Products R&D, Inc., Optinose US Inc.

Conditions

Mild to Moderate AsthmaPersistent Asthma

Phase 1

A Study to Compare the Bioavailability Intranasal Administration of 200 and 400 µg or 400 µg Alone of OPTINOSE™ FLUTICASONE With 440 µg of Flovent® HFA (Fluticasone Propionate) Inhalation Aerosol (Part 2)

CompletedNCT02266927

Optinose US Inc.Mild to Moderate Asthma

Start: 2014-09-30End: 2015-04-30Updated: 2016-02-03

Phase 3

Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma

CompletedNCT02175771

Teva Branded Pharmaceutical Products R&D, Inc.Persistent Asthma

Start: 2014-07-31End: 2015-07-31Updated: 2021-11-09

Related Papers

A Randomized Comparison of the Pharmacokinetics and Bioavailability of Fluticasone Propionate Delivered via Xhance Exhalation Delivery System Versus Flonase Nasal Spray and Flovent HFA Inhalational Aerosol

Clinical Therapeutics2019-11-0121 citations

A 6-month safety and efficacy study of fluticasone propionate and fluticasone propionate/salmeterol multidose dry powder inhalers in persistent asthma

Allergy and Asthma Proceedings2017-05-2514 citations

Dose-ranging study of salmeterol using a novel fluticasone propionate/salmeterol multidose dry powder inhaler in patients with persistent asthma

Allergy and Asthma Proceedings2016-05-2411 citations